Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses

被引：0

作者：

Harrison, Simon ^{[1
,2
]}

Riley, Caroline Hasselbalch ^{[3
]}

Manier, Salomon ^{[4
]}

Yoon, Sung-Soo ^{[5
]}

Pinto, Antonio ^{[6
]}

Cazaubiel, Titouan ^{[7
]}

Guidetti, Anna ^{[8
]}

Popat, Rakesh ^{[9
]}

Touzeau, Cyrille ^{[10
]}

Ocio, Enrique ^{[11
]}

Offner, Fritz ^{[12
]}

Rodriguez-Otero, Paula ^{[13
]}

Rizzello, Ilaria ^{[14
,15
]}

Mateos, Maria-Victoria ^{[16
]}

Broeske, Ann-Marie ^{[17
]}

Dekhtiarenko, Iryna ^{[18
]}

Dimier, Natalie ^{[19
]}

Eckmann, Jan ^{[17
,18
]}

Helms, Hans-Joachin ^{[20
]}

Jacob, Wolfgang ^{[17
]}

Schneider, Meike ^{[20
]}

Sleiman, Nassim ^{[20
]}

Weisser, Martin ^{[17
]}

Carlo-Stella, Carmelo ^{[21
,22
]}

机构：

[1] Univ Melbourne, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[2] Univ Melbourne, Royal Melbourne Hosp, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia

[3] Rigshospitalet, Copenhagen, Denmark

[4] CHU Lille, Lille, France

[5] Seoul Natl Univ, Coll Med, Seoul, South Korea

[6] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy

[7] CHU Bordeaux, Bordeaux, France

[8] Ist Nazl Tumori, Milan, Italy

[9] NHS Univ Coll London Hosp, London, England

[10] CHU Nantes, Nantes, France

[11] Marques Valdecilla Univ Hosp, Santander, Spain

[12] Univ Ziekenhuis Gent, Ghent, Belgium

[13] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

[14] Univ Bologna, Ist Ematol Seragnoli, IRCCS Azienda Ospedo, Bologna, Italy

[15] Univ Bologna, Bologna, Italy

[16] Univ Hosp Salamanca, IBSAL, CIC, CIBERONC, Salamanca, Spain

[17] Roche Innovat Ctr Munich, Penzberg, Germany

[18] Roche Innovat Ctr Zurich, Zurich, Switzerland

[19] Roche Innovat Ctr Welwyn, Welwyn Garden City, England

[20] Roche Innovat Ctr Basel, Basel, Switzerland

[21] Humanitas Univ, Humanitas Clin & Res Ctr, Dept Oncol & Hematol, Humanitas Canc Ctr, Rozzano, Italy

[22] Humanitas Univ, Dept Biomed Sci, Rozzano, Italy

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA-05

引用

页码：S3 / S4

页数：2

共 50 条

[1] Management considerations for dermatologic toxicities associated with talquetamab, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma
Purcell, Kiah
Catamero, Donna
Dai, Victoria
Feuer, Julia
Giacoia, Leora
Leon, Yan
Lurie, Alaina
Mitchell, Emily
Ray, Chloe
Urena, Annel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S312 - S313
[2] MANAGEMENT CONSIDERATIONS FOR DERMATOLOGIC TOXICITIES ASSOCIATED WITH TALQUETAMAB, A GPRC5DxCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Esler, Elaine
Ray, Chloe
Hefner, Kayla
O'Rourke, Lisa
Gray, Kathleen
Gray, Kathleen
McCluggage, Julie
ONCOLOGY NURSING FORUM, 2024, 51 (02)
[3] MANAGEMENT CONSIDERATIONS FOR ORAL TOXICITIES ASSOCIATED WITH TALQUETAMAB, A GPRC5DxCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
Shenoy, Samantha
Leahey, Sheryl
Catamero, Donna
O'Rourke, Lisa
Gray, Kathleen
Rogers, Stephanie
ONCOLOGY NURSING FORUM, 2024, 51 (02)
[4] Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
Schinke, Carolina D.
Touzeau, Cyrille
Minnema, Monique C.
van de Donk, Niels W. C. J.
Rodriguez-Otero, Paula
Mateos, Maria-Victoria
Rasche, Leo
Ye, Jing Christine
Vishwamitra, Deeksha
Ma, Xuewen
Qin, Xiang
Campagna, Michela
Masterson, Tara J.
Hilder, Brandi
Tolbert, Jaszianne A.
Renaud, Thomas
Goldberg, Jenna
Heuck, Christoph
Chari, Ajai
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] Pivotal Phase 2 MonumenTAL-1 results of Talquetamab (tal), a GPRC5DxCD3 Bispecific Antibody (BsAb), for Relapsed/Refractory Multiple Myeloma (RRMM)
Schinke, C.
Touzeau, C.
Minnema, M. C.
van de Donk, N. W.
Rodriguez-Otero, P.
Mateos, M. -V.
Rasche, L.
Ye, J. C.
Vishwamitra, D.
Ma, X.
Qin, X.
Campagna, M.
Masterson, T.
Hilder, B.
Tolbert, J.
Renaud, T.
Goldberg, J.
Heuck, C.
Chari, A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 82 - 83
[6] Practical management of patients with relapsed/refractory multiple myeloma receiving talquetamab, a GPRC5DxCD3 bispecific antibody: experience in monumenTAL-1
Catamero, Donna
Purcell, Kiah
Ray, Chloe
Giacoia, Leora
Leahey, Sheryl
Born, Patricia
Kruyswijk, Sandy
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S314 - S315
[7] Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma
Verkleij, Christie P. M.
Broekmans, Marloes E. C.
van Duin, Mark
Frerichs, Kristine A.
Kuiper, Rowan
de Jonge, A. Vera
Kaiser, Martin
Morgan, Gareth
Axel, Amy
Boominathan, Rengasamy
Sendecki, Jocelyn
Wong, Amy
Verona, Raluca, I
Sonneveld, Pieter
Zweegman, Sonja
Adams, Homer C., III
Mutis, Tuna
van de Donk, Niels W. C. J.
BLOOD ADVANCES, 2021, 5 (08) : 2196 - 2215
[8] Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Rasche, Leo
Schinke, Carolina
Touzeau, Cyrille
Minnema, Monique C.
van de Donk, Niels W. C. J.
Rodriguez-Otero, Paula
Mateos, Maria-Victoria
Ye, Jing Christine
Vishwamitra, Deeksha
Singh, Indrajeet
Qin, Xiang
Campagna, Michela
Masterson, Tara
Hilder, Brandi W.
Tolbert, Jaszianne
Renaud, Thomas
Heuck, Christoph
Kane, Colleen
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S561 - S562
[9] Efficacy and Safety of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Japanese Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 Monumental-1 Study
Ito, Shigeki
Kuroda, Yoshiaki
Sunami, Kazutaka
Matsue, Kosei
Imada, Kazunori
Tamura, Hideto
Takamoto, Mikihiro
Yamazaki, Hiroshi
Fujikawa, Ei
Pei, Lixia
Masterson, Tara J.
Campagna, Michela
Lau, Bonnie W.
Takamatsu, Yasushi
BLOOD, 2024, 144 : 7011 - 7012
[10] Talquetamab, a GPRC5DXCD3 Bispecific Antibody, for Treatment of Relapsed/Refractory Multiple Myeloma in Patients With Prior Exposure to BCMA Targeted Therapies - a "Real World" Study
Shkury, Eden
Hellou, Tamer
Nevo, Lee
Avigdor, Abraham
Magen, Hila
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S88 - S89

← 1 2 3 4 5 →